Liraglutide Modulates Adipokine Expression During Adipogenesis, Ameliorating Obesity, and Polycystic Ovary Syndrome in Mice

Overview

Journal Endocrine

Specialty Endocrinology

Date 2019 Mar 25

PMID 30904998

Citations 5

Authors

Anusha Singh

Joseph R D Fernandes

Gagan Chhabra

Amitabh Krishna

Arnab Banerjee

Affiliations

Soon will be listed here.

Abstract

Purpose: The incidence of obesity is increasing among all age groups throughout the world and it is highly associated with numerous other metabolic disorders, such as insulin resistance, polycystic ovarian syndrome (PCOS) etc. METHODS AND RESULTS: Using in vitro and in vivo approach, this study investigated the adipokine profile after liraglutide on differentiated murine 3T3-L1 pre-adipocytes. Effect of liraglutide on DHEA-induced PCOS mice were investigated. This study showed Liraglutide treatment resulted in up-regulation of adiponectin and IL-6 along with down-regulation of ICAM 1 in differentiated 3T3-L1 cells. Liraglutide in absence of other differentiating factors, significantly increased glucose, lipid uptake and PPARγ, C/EBPα expression in the adipocytes suggesting its ability to solely promote pre-adipocyte differentiation into mature adipocyte. Liraglutide treatment showed increased adiponectin expression and decreased number of cystic follicles, body weight, circulating glucose, triglyceride and testosterone levels in comparison to the PCOS induced mice.

Conclusion: This study suggests that adiponectin may act as a link between metabolic disorders and PCOS and that liraglutide might be a promising therapeutic agent for the treatment of PCOS in addition to obesity and insulin resistance.

Citing Articles

Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.

Zhou L, Qu H, Yang L, Shou L BMC Endocr Disord. 2023; 23(1):245.

PMID: 37940910 PMC: 10631119. DOI: 10.1186/s12902-023-01500-5.

Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose....

Zhang Y, Lin Y, Li G, Yuan Y, Wang X, Li N Biol Reprod. 2023; 108(6):945-959.

PMID: 36930063 PMC: 10266951. DOI: 10.1093/biolre/ioad032.

Free fatty acid receptors in the endocrine regulation of glucose metabolism: Insight from gastrointestinal-pancreatic-adipose interactions.

Zhao Y Front Endocrinol (Lausanne). 2022; 13:956277.

PMID: 36246919 PMC: 9554507. DOI: 10.3389/fendo.2022.956277.

Anti-Proliferative Activity of Glucagon-Like Peptide-1 Receptor Agonist on Obesity-Associated Breast Cancer: The Impact on Modulating Adipokines' Expression in Adipocytes and Cancer Cells.

Alanteet A, Attia H, Shaheen S, Alfayez M, Alshanawani B Dose Response. 2021; 19(1):1559325821995651.

PMID: 33746653 PMC: 7903831. DOI: 10.1177/1559325821995651.

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.

Abdalla M, Deshmukh H, Atkin S, Sathyapalan T Ther Adv Endocrinol Metab. 2021; 12:2042018821989238.

PMID: 33552465 PMC: 7844452. DOI: 10.1177/2042018821989238.

References

Qu F, Wang F, Lu X, Dong M, Sheng J, Lv P . Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway. Hum Reprod. 2010; 25(6):1441-50. DOI: 10.1093/humrep/deq078. View

Ravassa S, Zudaire A, Carr R, Diez J . Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol. 2011; 300(4):H1361-72. DOI: 10.1152/ajpheart.00885.2010. View

Svendsen P, Nilas L, Madsbad S, Holst J . Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism. 2009; 58(5):586-93. DOI: 10.1016/j.metabol.2008.11.009. View

Knudsen L, Nielsen P, Huusfeldt P, Johansen N, Madsen K, Pedersen F . Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43(9):1664-9. DOI: 10.1021/jm9909645. View

Li X, Jiang L, Yang M, Wu Y, Sun S, Sun J . CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes. Endocr J. 2014; 61(12):1153-62. DOI: 10.1507/endocrj.EJ14-0161. View

Chen H, Simar D, Pegg K, Saad S, Palmer C, Morris M . Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents. Diabetologia. 2013; 57(3):614-22. DOI: 10.1007/s00125-013-3132-5. View

Hunzicker-Dunn M, Lopez-Biladeau B, Law N, Fiedler S, Carr D, Maizels E . PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc Natl Acad Sci U S A. 2012; 109(44):E2979-88. PMC: 3497822. DOI: 10.1073/pnas.1205661109. View

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos N, Janez A . Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2013; 170(3):451-9. PMC: 3922503. DOI: 10.1530/EJE-13-0797. View

Ban K, Kim K, Cho C, Sauve M, Diamandis E, Backx P . Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology. 2010; 151(4):1520-31. DOI: 10.1210/en.2009-1197. View

10.

Nylander M, Frossing S, Clausen H, Kistorp C, Faber J, Skouby S . Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017; 35(1):121-127. DOI: 10.1016/j.rbmo.2017.03.023. View

11.

Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R . Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002; 26(7):883-96. DOI: 10.1038/sj.ijo.0801994. View

12.

Berg A, Scherer P . Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96(9):939-49. DOI: 10.1161/01.RES.0000163635.62927.34. View

13.

Iwase A, Goto M, Harata T, Takigawa S, Nakahara T, Suzuki K . Insulin attenuates the insulin-like growth factor-I (IGF-I)-Akt pathway, not IGF-I-extracellularly regulated kinase pathway, in luteinized granulosa cells with an increase in PTEN. J Clin Endocrinol Metab. 2009; 94(6):2184-91. DOI: 10.1210/jc.2008-1948. View

14.

Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R . Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab. 1995; 80(2):654-8. DOI: 10.1210/jcem.80.2.7852532. View

15.

Fu Y, Luo N, Klein R, Garvey W . Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005; 46(7):1369-79. DOI: 10.1194/jlr.M400373-JLR200. View

16.

Canipari R, Cellini V, Cecconi S . The ovary feels fine when paracrine and autocrine networks cooperate with gonadotropins in the regulation of folliculogenesis. Curr Pharm Des. 2012; 18(3):245-55. DOI: 10.2174/138161212799040411. View

17.

Aydin K, Arusoglu G, Koksal G, Cinar N, Yazgan Aksoy D, Yildiz B . Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014; 81(4):588-92. DOI: 10.1111/cen.12468. View

18.

Wang D, Haile A, Jones L . Rosiglitazone-induced adipogenesis in a bone marrow mesenchymal stem cell line - biomed 2011. Biomed Sci Instrum. 2011; 47:213-21. View

19.

Lehmann J, Moore L, Wilkison W, Willson T, Kliewer S . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995; 270(22):12953-6. DOI: 10.1074/jbc.270.22.12953. View

20.

Jensterle M, Kravos N, Goricar K, Janez A . Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017; 17(1):5. PMC: 5286837. DOI: 10.1186/s12902-017-0155-9. View